Form 4: Akari CEO Boosts Stake with Warrant Acquisitions

Akari Therapeutics CEO and Director Abizer Gaslightwala acquired significant warrants and pre-funded warrants through a private placement and a note exchange, pending shareholder approval.

Summary

• Abizer Gaslightwala, CEO and Director of Akari Therapeutics Plc, acquired derivative securities on December 16, 2025.
• Acquired 309,328 unregistered pre-funded warrants (PIPE PFWs) and 309,328 Series G Warrants in a private placement for a combined purchase price of $0.4041 per unit.
• Acquired 773,323 unregistered pre-funded warrants and 804,790 unregistered warrants by exchanging an outstanding unsecured promissory note held by the Reporting Person.
• The exercise price for Series G Warrants and Note Exchange Unregistered Warrants is $0.3883 per American Depositary Share (ADS).
• The exercise price for PIPE PFWs and Note Exchange Unregistered Pre-Funded Warrants is $0.00001 per ADS.
• All acquired warrants and pre-funded warrants require shareholder approval to become exercisable.
• Each ADS represents 2,000 Ordinary Shares of the Issuer.

Sentiment

Score: 7

Explanation: The CEO's acquisition of a significant number of warrants and pre-funded warrants, both through a private placement and a debt-to-equity exchange, generally indicates a strong vote of confidence in the company's future. While potential dilution exists, the insider buying aspect is typically viewed positively by investors.

Positives

• CEO Abizer Gaslightwala increased his beneficial ownership in Akari Therapeutics, signaling confidence in the company's future.
• The private placement and note exchange transactions provide capital or restructure debt for the company.
• The acquisition of pre-funded warrants with a nominal exercise price ($0.00001) offers a low-cost way for the CEO to increase equity ownership.

Negatives

• The transactions involve the issuance of new warrants and pre-funded warrants, which could lead to future dilution for existing shareholders upon exercise.
• The exercisability of all acquired securities is contingent upon shareholder approval, introducing an element of uncertainty.
• The note cancellation and exchange with the CEO represents a related-party transaction, which always warrants scrutiny.

Risks

• Shareholder approval is required for the warrants and pre-funded warrants to become exercisable; failure to obtain approval would impact the CEO's ability to convert these securities.
• Future exercise of these warrants and pre-funded warrants will result in dilution of existing shareholders' equity.
• The company's stock price performance could impact the value and incentive for the CEO to exercise these derivative securities.

Future Outlook

The future outlook is contingent on shareholder approval for the exercisability of the acquired warrants and pre-funded warrants. Once approved, these securities will allow the CEO to increase his equity stake in the company, with some having a five-year term and others exercisable until fully utilized.

Industry Context

Insider transactions, particularly by a CEO, are often viewed by the market as a signal of management's confidence in the company's prospects. Private placements and debt-to-equity conversions (via warrants) are common mechanisms for companies, especially in the biotech or smaller cap space, to raise capital or restructure their balance sheets. The requirement for shareholder approval for exercisability is a standard governance practice for certain types of equity issuances.

Related Party Transactions

• The company entered into a note cancellation and exchange agreement with Abizer Gaslightwala, the CEO and a Director, converting his outstanding unsecured promissory note into unregistered pre-funded warrants and unregistered warrants.

Stakeholder Impact

• Shareholders: Potential future dilution upon exercise of the warrants and pre-funded warrants, but also a signal of management confidence.
• Creditors: The conversion of the CEO's promissory note reduces the company's debt obligations to that specific creditor.

Next Steps

• Shareholder approval is required for the acquired warrants and pre-funded warrants to become exercisable.
• The CEO may exercise the warrants and pre-funded warrants in the future, subject to approval and market conditions.

Key Dates

Keywords

Akari Therapeutics, AKTX, Form 4, Insider Trading, Abizer Gaslightwala, Warrants, Pre-Funded Warrants, Private Placement, Note Exchange, Shareholder Approval, Beneficial Ownership, CEO, Director, SEC Filing